ANNAPOLIS, Md., Sept. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc.
(Amex: PIP), a biodefense company specializing in the development and
commercialization of medical countermeasures against chemical and
biological terrorism, announced today the Department of Health and Human
Services has published an award notice, dated September 21, 2007, in the
amount of $13,920,347, listing PharmAthene as the contractor, relating to
the development of therapeutic agents for selected bacterial diseases.
PharmAthene has not received an executed agreement from the Department of
Health and Human Services and expects to provide further information if and
when such an executed agreement is received.
About PharmAthene, Inc.
PharmAthene (Amex: PIP) was formed to meet the critical needs of the
United States and its Allies by developing and commercializing medical
countermeasures against biological and chemical weapons. PharmAthene's lead
programs include Valortim(TM) for the prevention and treatment of anthrax
infection and Protexia(R) for the prevention and treatment of morbidity and
mortality associated with exposure to chemical nerve agents. For more
information on PharmAthene, please visit http://www.PharmAthene.com.
SOURCE PharmAthene, Inc.
 back to top
Related links:
http://www.pharmathene.com/
CONTACT:
Stacey Jurchison, Director, Corporate
Communications of PharmAthene, Inc., +1-410-269-2610, Cell:
+1-410-474-8200, JurchisonS@PharmAthene.com
|
